Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Urology Associates PC

Neither a doctor nor a teaching hospital

Research payments

$6,709,294

651 payments

Through program year 2025, Urology Associates PC is reported as receiving $6,709,294 in research payments, across 651 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $682,845 79
2024 Research $997,097 101
2023 Research $843,494 66
2022 Research $1,502,352 60
2021 Research $473,077 56
2020 Research $1,200,495 160
2019 Research $1,009,934 129

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $1,915,319 257 payments
  2. Pfizer Inc. $1,817,801 90 payments
  3. Merck Sharp & Dohme Corporation $1,523,861 51 payments
  4. Clovis Oncology, Inc. $644,201 23 payments
  5. Sumitomo Pharma America, Inc. $298,011 38 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $177,019 128 payments
  7. AbbVie, Inc. $66,149 13 payments
  8. pharmaand GmbH $53,132 4 payments
  9. Telix Pharmaceuticals $42,000 1 payment
  10. Allergan Inc. $38,559 16 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 $1,134,035 2 payments
  2. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $793,564 14 payments
  3. A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) $644,201 23 payments
  4. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $496,970 10 payments
  5. Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions $477,504 53 payments
  6. A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc $383,514 22 payments
  7. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $315,790 31 payments
  8. A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC $277,866 41 payments
  9. A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) $242,490 21 payments
  10. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $212,993 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record